nicardipine has been researched along with felodipine in 27 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 3 (11.11) | 18.7374 |
1990's | 8 (29.63) | 18.2507 |
2000's | 10 (37.04) | 29.6817 |
2010's | 6 (22.22) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Arrowsmith, JE; Blackburn, KJ; Burges, RA; Campbell, SF; Cross, PE; Gardiner, DG; Stubbs, JK | 1 |
Coassolo, P; Lavé, T; Schneider, G | 1 |
Topliss, JG; Yoshida, F | 1 |
Casciano, CN; Clement, RP; Johnson, WW; Wang, EJ | 1 |
Bruno-Blanch, L; Gálvez, J; García-Domenech, R | 1 |
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
Sun, H | 1 |
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
Bakmiwewa, SM; Ball, HJ; Fatokun, AA; Hunt, NH; Payne, RJ; Tran, A | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Sharma, RK; Wang, JH; Wu, Z | 2 |
Dong, H; Lu, YQ; Wang, Q; Yang, QQ; Yang, ZC | 1 |
Imai, S; Mitomi, A; Nakazawa, M; Tanaka, M; Yoshida, Y | 1 |
Littler, WA; Smith, SA | 1 |
Barbieri, L; Camerini, F; Mestroni, L | 1 |
Kikuchi, K; Sugawara, H; Tobise, K | 1 |
White, CM | 1 |
Seibold, JR; Sturgill, MG | 1 |
Jordan, PJ; Littler, WA; Stallard, TJ; Vaile, JC | 1 |
Bollo, S; Bontá, M; Caballero, E; Maya, JD; Medarde, M; Morello, A; Núñez-Vergara, LJ; Puebla, P; Repetto, Y; Rodriguez, A; San Feliciano, A; Squella, JA; Tellez, R; Zelada, U | 1 |
Sahney, S | 1 |
5 review(s) available for nicardipine and felodipine
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Antihypertensive agents--the race for third place.
Topics: Adrenergic alpha-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Blockers; Captopril; Diazoxide; Felodipine; Humans; Hydralazine; Indoramin; Labetalol; Minoxidil; Nicardipine; Nifedipine; Vasodilator Agents; Verapamil | 1985 |
[Calcium antagonists in congestive heart failure].
Topics: Calcium Channel Blockers; Cardiomyopathy, Dilated; Diltiazem; Felodipine; Heart Failure; Hemodynamics; Humans; Nicardipine; Nifedipine; Nisoldipine; Nitrendipine; Verapamil | 1988 |
Calcium channel blockers in left ventricular dysfunction or congestive heart failure.
Topics: Amlodipine; Calcium Channel Blockers; Clinical Trials as Topic; Diltiazem; Felodipine; Heart Failure; Humans; Nicardipine; Nifedipine; Ventricular Dysfunction, Left; Verapamil | 1997 |
A review of calcium channel antagonists in the treatment of pediatric hypertension.
Topics: Amiodarone; Calcium Channel Blockers; Child; Felodipine; Humans; Hypertension; Isradipine; Nicardipine; Nifedipine; Verapamil | 2006 |
22 other study(ies) available for nicardipine and felodipine
Article | Year |
---|---|
Long-acting dihydropyridine calcium antagonists. 1. 2-Alkoxymethyl derivatives incorporating basic substituents.
Topics: Amlodipine; Animals; Biological Assay; Biological Availability; Calcium Channel Blockers; Chemical Phenomena; Chemistry; Dihydropyridines; Dogs; Guinea Pigs; Hemodynamics; Kinetics; Male; Nifedipine; Pyridines; Rats; Vasoconstriction | 1986 |
Combining in vitro and in vivo pharmacokinetic data for prediction of hepatic drug clearance in humans by artificial neural networks and multivariate statistical techniques.
Topics: Animals; Biological Availability; Dogs; Humans; Least-Squares Analysis; Liver; Multivariate Analysis; Neural Networks, Computer; Pharmacokinetics; Rats | 1999 |
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors.
Topics: 3T3 Cells; Adrenergic Uptake Inhibitors; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Binding Sites; Biological Transport, Active; Cell Line; Cell Separation; Cell Survival; Flow Cytometry; Fluorescent Dyes; Humans; Inhibitory Concentration 50; Mice; Protein Binding; Reserpine; Spectrometry, Fluorescence; Substrate Specificity; Time Factors | 2001 |
Topological virtual screening: a way to find new anticonvulsant drugs from chemical diversity.
Topics: Anticonvulsants; Computer Simulation; Databases, Factual; Discriminant Analysis; Drug Design; Molecular Structure; Quantitative Structure-Activity Relationship | 2003 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Capture hydrolysis signals in the microsomal stability assay: molecular mechanisms of the alkyl ester drug and prodrug metabolism.
Topics: Carboxylic Acids; Cytochrome P-450 Enzyme System; Esters; Humans; Hydrolysis; Microsomes; Models, Molecular; Molecular Structure; Prodrugs; Quantum Theory; Signal Transduction | 2012 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Identification of selective inhibitors of indoleamine 2,3-dioxygenase 2.
Topics: Animals; Dose-Response Relationship, Drug; Enzyme Inhibitors; HEK293 Cells; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Mice; Models, Molecular; Molecular Structure; Structure-Activity Relationship; Substrate Specificity | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
[The mechanism of inhibition of calmodulin-dependent cyclic nucleotide phosphodiesterase by dihydropyridine calcium antagonists].
Topics: Binding, Competitive; Cyclic Nucleotide Phosphodiesterases, Type 1; Felodipine; Nicardipine; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases | 1992 |
Antagonistic effects of dihydropyridines and verapamil on CaCl2 and 5-HT-evoked contraction in porcine coronary artery.
Topics: Animals; Calcium Chloride; Coronary Vessels; Dihydropyridines; Felodipine; In Vitro Techniques; Muscle Contraction; Muscle, Smooth, Vascular; Nicardipine; Nifedipine; Nimodipine; Serotonin Antagonists; Swine; Verapamil | 1991 |
Effects of calcium antagonists, felodipine and nicardipine, on cerebral circulation in dogs.
Topics: Animals; Blood Pressure; Calcium Channel Blockers; Cerebrovascular Circulation; Dogs; Dose-Response Relationship, Drug; Felodipine; Female; Heart Rate; Hemodynamics; Male; Nicardipine; Oxygen Consumption | 1990 |
Antioxidant effects of calcium antagonists on rat myocardial membrane lipid peroxidation.
Topics: Adenosine Diphosphate; Animals; Antioxidants; Calcium Channel Blockers; Cell Membrane; Dihydropyridines; Diltiazem; Felodipine; Fumarates; Heart; Iron; Lipid Peroxidation; Male; Myocardium; Nicardipine; Nifedipine; Nisoldipine; Nitrendipine; Oxidation-Reduction; Rats; Rats, Sprague-Dawley; Verapamil | 1996 |
Mechanisms of inhibition of calmodulin-stimulated cyclic nucleotide phosphodiesterase by dihydropyridine calcium antagonists.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Binding, Competitive; Brain; Calcium; Calcium Channel Blockers; Calmodulin; Cattle; Cyclic Nucleotide Phosphodiesterases, Type 1; Dihydropyridines; Felodipine; Isoenzymes; Molecular Weight; Nicardipine; Phosphodiesterase Inhibitors | 1997 |
Rational use of calcium-channel antagonists in Raynaud's phenomenon.
Topics: Amlodipine; Calcium Channel Blockers; Diltiazem; Felodipine; Humans; Isradipine; Nicardipine; Nifedipine; Raynaud Disease | 1998 |
The effects of acute and chronic dihydropyridine calcium antagonist therapy on baroreflex sensitivity: a re-analysis using the sequence method.
Topics: Adult; Baroreflex; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Calcium Channel Blockers; Cardiology; Felodipine; Female; Heart Rate; Humans; Hypertension; Male; Middle Aged; Nicardipine; Time Factors | 2000 |
Effects of 3-chloro-phenyl-1,4-dihydropyridine derivatives on Trypanosome cruzi epimastigotes.
Topics: Animals; Calcium Channel Blockers; Cell Movement; Dihydropyridines; Electrochemistry; Felodipine; Nicardipine; Oxidation-Reduction; Oxygen Consumption; Trypanocidal Agents; Trypanosoma cruzi | 2000 |